Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Chronic Lymphocytic Leukemia (CLL) · Chronic Lymphocytic Leukemia · APVO

Aptevo Therapeutics

Aptevo Therapeutics patent portfolio — 13 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Seattle, USA HQ
2016 Founded
54 Employees
Public company Type
APVO · NYSE Ticker
Company details
Status
Public
HQ
Seattle, USA
Founded
2016
Employees
54
Programs
9
Drugs
4
Patents
13
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Aptevo Therapeutics patents

13 pharmaceutical patents indexed for Aptevo Therapeutics. 0 expire within 24 months.

Aptevo Therapeutics has 13 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

13 patents

Patent portfolio

  1. US 11939392

    CD123 binding proteins and related compositions and methods

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11725060

    Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11352426

    CD3 binding polypeptides

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11312786

    Oncofetal antigen binding proteins and related compositions and methods

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11242400

    CD123 binding proteins and related compositions and methods

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10676533

    Methods of treatment of CD123 overexpressing disorders

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10307481

    CD37 immunotherapeutics and uses thereof

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10239949

    Oncofetal antigen binding proteins and related compositions and methods

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10202452

    CD3 binding polypeptides

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10143748

    B-cell reduction using CD37-specific and CD20-specific binding molecules

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9782478

    Prostate-specific membrane antigen binding proteins and related compositions and methods

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9587008

    Method of producing recombinant vitamin K dependent proteins

    Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9493564

    CD86 antagonist multi-target binding proteins

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Aptevo Therapeutics have?

13 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Aptevo Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.